FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体
产品名称： FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体
英文名称： Anti-RANKL/CD254/FITC
产品编号： HZ-0747R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： Flow-Cyt=1:50-200 IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749 点击查看
- 传真 : 点击查看
- 邮箱 : www.shzbio.net
- 二维码 : 点击查看
Rabbit Anti-RANKL/CD254/FITC Conjugated antibody
FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体
| 英文名称 | Anti-RANKL/CD254/FITC |
| 中文名称 | FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体 |
| 别 名 | OPGL; CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_HUMAN. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 细胞生物 免疫学 发育生物学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Dog, |
| 产品应用 | Flow-Cyt=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 35kDa |
| 细胞定位 | 细胞膜 |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human OPGL |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008]. Function: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Subcellular Location: Cytoplasm; Secreted and Cell membrane. Tissue Specificity: Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. Post-translational modifications: The soluble form of isoform 1 derives from the membrane form by proteolytic processing. The cleavage may be catalyzed by ADAM17. DISEASE: Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. Similarity: Belongs to the tumor necrosis factor family. Database links: Entrez Gene: 8600 Human Entrez Gene: 21943 Mouse Omim: 602642 Human SwissProt: O14788 Human SwissProt: O35235 Mouse Unigene: 333791 Human Unigene: 249221 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. OPGL骨保护蛋白配体又称骨保护素配体(破骨细胞发育刺激因子)。属肿瘤坏死因子TNF-a家族。 OPGL促进破骨细胞的分化和活性,而OPG抑制这些过程。骨髓瘤细胞影响骨髓中这两种蛋白的生理平衡，是发生溶骨性病变的根本所在 |
该基因编码肿瘤坏死因子（TNF）细胞因子家族的成员，TNF是骨保护素的配体，是破骨细胞分化和活化的关键因子。该蛋白是树突状细胞存活因子，参与调节T细胞依赖的免疫应答。据报道，T细胞活化诱导该基因的表达，并导致破骨细胞生成和骨丢失的增加。该蛋白通过涉及SRC激酶和肿瘤坏死因子受体相关因子（TRAF）6的信号复合物激活抗凋亡激酶AKT/PKB，表明该蛋白可能在细胞凋亡的调节中起作用。小鼠体内相关基因的靶向破坏导致严重的骨硬化症和破骨细胞缺乏。缺失小鼠在妊娠期T淋巴细胞和B淋巴细胞的早期分化存在缺陷，未能形成小叶-肺泡乳房结构。已经发现两个交替剪接转录变体。[ RefSeq，JUL 2008 ]提供。